# Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC

> **NCT07110103** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 20 (estimated)

## Conditions studied

- SCLC
- SCLC, Extensive Stage

## Interventions

- **DRUG:** golidocitinib with PD-1 inhibitors

## Key facts

- **NCT ID:** NCT07110103
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-31
- **Primary completion:** 2027-03-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07110103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07110103, "Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07110103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*